Tucatinib + Abemaciclib + Herceptin for HER2+ MBC
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Tucatinib|DRUG: Abemaciclib|DRUG: Trastuzumab|DRUG: Aromatase Inhibitor
Sponsor: Dana-Farber Cancer Institute
Collaborators: Eli Lilly and Company